RYSTIGGO 140 mg/mL
ROZANOLIXIZUMAB · INJECTION, SOLUTION · UCB, Inc.
No Recall History
Plain English
RYSTIGGO is a injection, solution containing rozanolixizumab at 140 mg/mL, taken subcutaneous. Manufactured by UCB, Inc..
Key Facts
- Brand Name
- RYSTIGGO
- Generic Name
- ROZANOLIXIZUMAB
- NDC Code (Product)
50474-983- Manufacturer
- UCB, Inc.
- Strength
- 140 mg/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761286
- Drug Class
- Neonatal Fc Receptor Blocker [EPC]
- Marketing Start
- 06/14/2024
Recall History
No Recall HistoryFrequently Asked Questions
What is RYSTIGGO used for?
RYSTIGGO contains ROZANOLIXIZUMAB. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is RYSTIGGO a controlled substance?
RYSTIGGO is not classified as a controlled substance by the DEA.
What is the generic name for RYSTIGGO?
The generic name for RYSTIGGO is ROZANOLIXIZUMAB. There are no other listed brand versions of ROZANOLIXIZUMAB.
What is the NDC code for RYSTIGGO 140 mg/mL?
The NDC (National Drug Code) for RYSTIGGO 140 mg/mL is 50474-983, listed by UCB, Inc..
Other RYSTIGGO Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)